Cardiac Imaging in Hypertrophic Cardiomyopathy by Lu, Dai-Yin & Hsiung, Ming-Chong
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Cardiac Imaging in Hypertrophic Cardiomyopathy
Dai-Yin Lu and Ming-Chong Hsiung
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/64364
Provisional chapter
Cardiac Imaging in Hypertrophic Cardiomyopathy
Dai-Yin Lu and Ming-Chong Hsiung
Additional information is available at the end of the chapter
Abstract
Hypertrophic cardiomyopathy (HCM) is a relatively common inherited cardiomyop‐
athy, which is occasionally challenging to differentiate from hypertensive heart disease
and athlete  hearts  on  the  basis  of  morphologic  or  functional  abnormalities  alone.
Imaging studies provide solutions for most clinical needs, from diagnosis, anatomical
and  functional  assessment,  family  screening,  risk  stratification,  to  monitoring  of
treatment  response.  Generally,  transthoracic  echocardiography is  used  as  first‐line
imaging tool to establish the diagnosis. A multimodality imaging approach (cardiac
magnetic resonance, cardiac computed tomography, and cardiac nuclear imaging) is
also encouraged in the assessment of these patients. The choice of imaging tool should
be based on a broad perspective and expert knowledge of what each technique has to
offer, including its specific advantages and disadvantages. In this chapter, we discuss
the utility and pitfalls of established imaging modalities and discuss the evolving role
of novel echocardiographic imaging modalities.
Keywords: cardiac computed tomography, cardiovascular magnetic resonance, echo‐
cardiography, hypertrophic cardiomyopathy, nuclear imaging
1. Introduction
1.1. Definition and prevalence
Hypertrophic  cardiomyopathy  (HCM)  is  the  most  common  inherited  cardiac  disease
presented with exercise intolerance, heart failure, cardiac arrhythmias and sudden cardiac
death [1]. Across different ethnicities, the prevalence is approximately 0.2% [2]. This estimated
frequency in the general population appears to exceed the relatively low visit of HCM in
cardiology  practices,  implying  that  the  most  affected  individuals  remain  undiagnosed,
probably in  most  cases  without  symptoms or  shortened life  expectancy [3].  The clinical
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diagnosis of HCM is based on the demonstration of asymmetric left ventricular hypertrophy
(LVH) with maximal wall thickness ≥15 mm, in the absence of other cardiac or systemic cause
that would produce such magnitude of hypertrophy.
1.2. Natural history and clinical course
The natural history is generally benign in vast majority of patients, with a life span close to
general population [4]. However, hemodynamic‐related symptoms secondary to dynamic left
ventricular outflow tract (LVOT) obstruction as well as myopathy‐related complications may
happen. Although symptoms may occur at any age, they are more common between young
adult and middle age. Development of symptoms at older age is generally associated with less
severe forms of the disease.
Although HCM presents primarily with ventricular septal hypertrophy, a key recognizable
feature has been dynamic LVOT obstruction and HCM has been regarded as a predominantly
obstructive disease [5]. Left ventricular outflow tract (LVOT) obstruction may be noted at rest
or during physiological exercise in 50–70% of the HCM patients [6]. LVOT obstruction at rest,
defined as ≥30 mmHg, is a strong, independent predictor for progression of heart failure and
death [7, 8]. Accordingly, current AHA/ACC/ESC guidelines classify HCM patients based on
their LVOT gradients into obstructive (resting and provoked gradients ≥30 mmHg); latent
obstructive (resting <30 and provoked ≥30 mmHg); non‐obstructive (resting and provoked
gradients <30 mmHg) [3, 4].
HCM also represents the most frequent cause of sudden cardiac death (SCD), one of the most
serious complications, in young athletes in countries without systematic sport screening
programs. Dynamic LVOT obstruction and disarrayed myocardial fiber impair diastolic
function of left ventricle, followed by enlargement of left atrium and heart failure with
preserved ejection fraction (EF). Atrial fibrillation (AF) is also a clinical presentation secondary
to left atrial enlargement, which may later cause cardioembolic events and the following
disability in the middle and older age groups.
2. The role of imaging in HCM
Multimodality imaging—echocardiography, cardiac magnetic resonance, cardiac computed
tomography, and cardiac nuclear imaging—provide comprehensive information. Patients with
HCM usually require long‐term follow‐up. It is suggested that transthoracic echocardiography
be performed every 1–2 years and cardiac magnetic resonance at least once after the diagnosis
is made, yet the strategy needs to be individualized (Table 1).
2.1. Role of echocardiography in evaluation of HCM (Table 2) [9]
2.1.1. Anatomical evaluation
HCM presents primarily with LVH, which progresses with time (Figure 1). The presentation
is rare when in childhood, and the growth of LVH becomes more obvious during adolescence.
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Other systemic causes of LVH (obesity, athlete heart, systemic hypertension, aortic stenosis, or
infiltrative disease) should be ruled out first before the diagnosis is confirmed. The pattern of
hypertrophy and LV volume can be analyzed by echocardiography. Ventricular volumes are
generally normal or slightly lower, and the biplane Simpson’s method has been applied to the
measurement of LV volumes and EF [10]. Three‐dimensional (3D) echocardiography has also
been shown to provide more accurate means of quantification, [11] yet the references for HCM
are limited.
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Table 1. Imaging tools in HCM.
Screening
LV Presence of hypertrophy and its distribution; report should include measurements f LV dimensions and
wall thickness (septal, posterior, and maximum)
Ejection fraction
Diastolic function (comments n LV relaxation and filling pressures)
Dynamic obstruction at rest and with Valsalva maneuver; report should identify the site of obstruction and
the gradient
MV Mitral valve and papillary muscle evaluation, including the direction, mechanism, and severity of mitral
regurgitation; if needed, TEE should be performed to satisfactorily answer these questions
RV RV hypertrophy and whether RV dynamic obstruction is present
PA Pulmonary artery systolic pressure
LA LA volume indexed to body surface area
Guidance TEE is recommended to guide surgical myectomy, and TTE or TEE for alcohol septal ablation
LA = left atrium; LV = left ventricle; MV = mitral valve; PA = pulmonary artery; RV = right ventricle; TEE =
transesophageal echocardiography (Adapted with permission from Nagueh et al. [9]).
Table 2. Echocardiogrophic evaluations of patients with HCM.
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Figure 1. Left ventricular thickness, evaluated at septum and free wall level, is considered abnormal when ≥ 15 mm,
and defined asymmetrical in presence of a septal to free wall thickness ratio between 1.3 and 1.5.
2.1.2. Hemodynamic evaluation
A key recognizable feature has been dynamic LVOT obstruction, and HCM has been regarded
as a predominantly obstructive disease [5]. Patients with LVOT obstruction, defined by the
presence of a peak gradient higher than 30 mmHg at rest or after provocative maneuvers
(Valsalva, standing, and exercise) is a strong, independent predictor for progression of heart
failure and death [7, 8] (Figure 2). Structural abnormalities of the mitral valve apparatus in
HCM include hypertrophy of the papillary muscles, resulting in anterior displacement of
papillary muscles, and mitral valve elongation [12, 13]. Systolic anterior motion (SAM) is
defined as the systolic motion of the mitral leaflet, mainly anterior leaflet, or chordae into LVOT,
resulting in outlet narrowing and flow disturbance. SAM also impairs the mitral leaflet
coaptation, followed by regurgitation (Figure 3). The anterior leaflet motion is greater than
that of the posterior leaflet during SAM and an interleaflet gap occurs, resulting in a typically
posteriorly directed jet of mitral regurgitation. The anterior leaflet has a greater surface area
and hence greater redundancy and mobility. If a concentric regurgitation jet is found in HCM
patients, concomitant mitral valvulopathy should be carefully evaluated.
2.1.3. Assessment of LV systolic function
The ejection fraction of left ventricle in HCM patients is generally normal or even increased.
However, patients with significant hypertrophy may have small LV end‐diastolic volumes and
the following lower stroke volumes despite a normal LVEF. LV systolic dysfunction is usually
Echocardiography in Heart Failure and Cardiac Electrophysiology118
defined as LVEF < 50%. When present, the prognosis is markedly worse. In addition to 2D
imaging, Doppler echocardiography has been used to assess subclinical LV systolic dysfunc‐
tion. Tissue Doppler imaging measures the velocity of myocardial motion. A lower systolic
(Sa) or reduced early diastolic (Ea or e′) velocities can occur before overt hypertrophy devel‐
ops [14].
Figure 2. (A) Asymmetric septal hypertrophy may cause narrowing of the left ventricular outflow tract, resulting in
turbulent flow. (B) Doppler analysis across the LVOT in dynamic obstructive HCM results in a characteristic signal
with a late‐peaking dagger‐shaped appearance.
2.1.4. Assessment of LV diastolic function
Reduction in ventricular compliance and increased stiffness due to myocardial fibrosis
coupled with a reduction of chamber volume and suction play a role in the pathophysiol‐
ogy of diastolic dysfunction in patients with HCM. LV and left atrial (LA) filling abnor‐
malities have been reported in patients with HCM, irrespective of the presence and extent
of LV hypertrophy. Tissue Doppler echocardiography indicates impaired myocardial relax‐
ation regardless of symptoms or severity of LVOT obstruction [15]. Although tissue Dop‐
pler echocardiography has been successfully used to estimate filling pressures in a variety
of cardiac disorders [16, 17], it is not as reliable in patients with hypertrophic cardiomy‐
opathy as in patients with left ventricular systolic dysfunction [18]. In a study consisting
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of 35 patients, LV filling pressures can be estimated with reasonable accuracy in HCM
patients by measuring mitral early diastolic inflow/flow propagation velocity or ratio of
early diastolic mitral flow velocity to the early diastolic mitral septal annulus motion ve‐
locity (E/e′) [19]. Whereas a later report with symptomatic HCM patients concluded Dop‐
pler echocardiographic estimates of left ventricular filling pressure with the use of
transmitral flow and mitral annular velocities correlated modestly with direct measure‐
ment of left atrial pressure [20]. Despite of this inconsistency in filling pressure estima‐
tion, tissue Doppler imaging remains a useful tool for risk stratification of patients with
HCM [21]. A higher septal E/e′ predicts patients with HCM who are at risk of sustained
ventricular tachycardia (VT), implantable cardioverter defibrillator (ICD) discharge, car‐
diac arrest or sudden cardiac death [22, 23].
Figure 3. Systolic anterior motion (SAM) of anterior mitral leaflet at mid to late systolic phase (A) parasternal long axis
view, 2D; (B) parasternal long axis view, M‐mode.
LA volume is mainly secondary to diastolic dysfunction, mitral regurgitation and atrial
myopathy. LA enlargement is generally assessed by 2D or M‐mode linear dimensions.
However, it is important to recognize that linear dimensions, particularly anteroposterior
measurements of the LA, may not measure true LA size, as LA remodeling frequently happens
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asymmetrically [24]. Increased LA volume is an independent indicator of functional capacity
[25] and an LA volume index of >34 ml/m2 has been shown to be predictive of a more severe
LVH, diastolic dysfunction, and adverse cardiovascular outcomes [26].
2.2. Role of deformation imaging in HCM
2.2.1. TDI-derived strain
Although tissue Doppler velocity was considered as a technique for evaluation of regional
myocardial performance, the utility is limited in distinguishing myocardial contractility from
passive motion. Such restriction later leads to the development of strain imaging. Strain is a
measure of tissue deformation and is defined as the change in length normalized to the original
length. The rate at which this change occurs is called strain rate (SR). In contrast to tissue
Doppler velocity, which examines myocardial motion relative to the transducer, strain
measures myocardial motion relative to the adjacent myocardium [27]. When the left ventricle
contracts, the myocardium shortens in longitudinal and circumferential direction (negative
value in strain) and thickens in the radial direction (positive value in strain) (Figure 4) [28].
Strain rate (SR) represents the local rate of myocardial deformation (Figure 5) [29]. Weidemann
et al. (30) firstly described the use of TDI-derived strain for the evaluation of HCM in a case
report of a child with non-obstructive HCM. Tissue Doppler velocities were found to be normal
in all the septal segments interrogated. However, systolic longitudinal strain SR was signifi-
cantly decreased in the mid septal region with no significant changes in the basal regions when
compared with healthy children [30]. Later reports also confirmed similar findings in adults
with HCM [31, 32].
Figure 4. Graphic representation of the principal myocardial deformations: longitudinal (A), radial and circumferential
(B), and torsion (C). The direction of deformation in systole is shown as solid lines and that in diastole is shown as
dashed lines. LONG indicates longitudinal; RAD, radial; and CIRC, circumferential. (Reprinted with permission from
Abraham et al. [28]).
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Figure 5. Strain analysis from tissue Doppler imaging from three representative regions of interest (ROIs) in LV septal
wall.
2.2.2. 2D strain or speckle tracking imaging
The interaction of ultrasound with the myocardium produces unique acoustic patterns, also
known as “speckles.” These speckles can be tracked over time and speckle displacement can
be used to calculate the tissue velocity and strain [33]. This method is not based on the Doppler
principle and relatively angle independent [34]. Deformation is calculated with frame‐by‐
frame speckle displacement, yielding angle independent parameters of myocardial contrac‐
tion, and gives longitudinal, transverse strain and strain rate in long‐axis images (Figure 6).
Similarly, radial and circumferential strain or strain rate may be analyzed by the short‐axis
images. In a study for patients with familial non‐obstructive HCM, average longitudinal was
reduced in affected individuals compared with healthy controls, despite apparently normal
systolic function. In addition, no significant difference in the values obtained by TDI versus
2D strain echocardiography was observed [35]. A recent study of patients with HCM and
preserved systolic function demonstrated attenuated longitudinal strain, increased circum‐
ferential strain, and normal overall systolic LV twist or torsion [36].
Figure 6. Strain analysis from two‐dimensional speckle tracking from apical four chamber view.
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2.3. Application of interventional echocardiography in HCM
2.3.1. Alcohol septal ablation (ASA)
2D echo is useful in search of suitable patients for ASA. During the procedure under trans‐
thoracic echocardiographic guidance, injection of echo contrast into a septal perforator branch
of the left anterior descending artery helps determine whether the selected branch to occlude
supplies the appropriate myocardium where SAM contacts interventricular septum (Fig‐
ure 7) [37]. For patients with suboptimal transthoracic echo window, transesophageal echo
imaging may be another option.
Figure 7. Myocardial contrast echocardiography of the hypertrophied septum after injection of sonicated albumin
(Contrast) and ethanol (Reprinted wth permission from Nagueh et al. [37]).
2.3.2. Surgical myectomy and mitral surgery
It is important to have a real‐time imaging analysis in the peri‐procedural assessment of HCM
patients undergoing myectomy, with or without mitral surgery. Intraoperative Transesopha‐
geal echocardiography (TEE) plays a key role in surgery, assessing mechanisms of LVOTO,
mechanism of MR, extension of myocardial region that need to be removed and other possible
intra‐operative complications.
2.4. Other imaging modality
2.4.1. Cardiac magnetic resonance (Table 3) [38]
2.4.1.1. Anatomical evaluation
Cardiac magnetic resonance (CMR) should be considered in the initial evaluation of all patients
with HCM when clinic resources are available [4]. It provides comprehensive evaluation of
both the ventricle, including assessment of wall thickness [39–41] and the chamber volumes,
with high quality of spatial and temporal resolution (Figure 8) [38]. CMR may be more sensitive
than echocardiography in detecting LVH [40]. The extension of LVH can be defined using CMR
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as focal (1–2 hypertrophic segments), intermediate (3–7 segments), and diffuse (8–16 hyper‐
trophic segments). CMR can also give more precise measurement in maximal diastolic wall
thickness [42].
Left ventricle volumes, mass and ejection fraction
Location, type, distribution of hypertrophy, maximal wall thickness and diastolic wall thickness to volume ratio
Degree of asymmetry
LVOT or mid‐cavity obstruction
LGE: presence or absence; pattern and extension
Evidence of MR
Description of mitral valve apparatus (leaflets, chordae, papillary muscles) and its relation to obstruction or MR
LGE = late gadolinium enhancement; LVOT = left ventricular outlet tract; MR = mitral regurgitation. (Adapted with
permission from Cardim et al. [38].)
Table 3. CMR evaluations of patients with HCM.
Figure 8. Cardiac MR in HCM patients. Cine CMR‐SSFP in different HCM patients. (A) Basal short‐axis view, asym‐
metric LVH with lateral wall sparing. (B) Three‐chamber view, mid‐ventricular hypertrophy of the medial segments of
the posterior wall and anterior interventricular septum. (C) short‐axis view, LVH localized in the anteroseptal wall (18
mm), undetected by echocardiography. (D) Three‐chamber view, systolic phase. (Reprinted with permission from Car‐
dim et al. [38]).
2.4.1.2. Tissue characterization
CMR is the most important technique in tissue characterization. The principle of late gadoli‐
nium enhancement (LGE) in CMR is based on those tissues, with an expanded extracellular
space that provides a larger distribution volume for the conventional CMR contrast agents,
which occupy extravascular and extracellular space. Within 30 minutes, differences between
the tissue with normal and expanded extracellular volumes are large and LGE imaging is
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acquired (Figure 9) [43]. Current LGE protocols provide a very high spatial resolution (≤1 mm)
and also provide a very high contrast to noise ratio, allowing to delineate small amounts of
myocardial fibrosis. In HCM patients, there is frequent [44] and progressive [45] fibrosis. Two
major patterns of LGE distribution are demonstrated: Intramural LGE was seen within the
hypertrophied segments, which are thought to be reflective of replacement fibrosis [46]. RV
insertion points LGE corresponds to interstitial fibrosis and myocyte disarray [47].
Figure 9. Pre‐ and post‐contrast CMR images demonstrating enhancement. The pre‐contrast images are the diastolic
frames of fast imaging with steady‐state precession cine loops. In the post‐contrast images, normal myocardium ap‐
pears dark. There is a large area of septal enhancement, with additional papillary muscle enhancement and subendo‐
cardial enhancement of the lateral wall. The total extent of enhancement was 25% of the left ventricular mass.
(Reprinted with permission from Moon et al. [43]).
2.4.2. Cardiac nuclear imaging
Single photon‐emission computed tomography (SPECT) myocardial perfusion imaging with
Thallium‐201 and Tc‐99 m labelled tracers often demonstrate reversible (suggestive of ische‐
mia) and fixed defects (scar), even when there is no obvious epicardial coronary artery disease
[48]. The positive predictive value for SPECT study in HCM is relatively low for epicardial
coronary artery disease compared to a high negative predictive value. Ischemic and scarring
have been demonstrated a predictor of worse outcome, including adverse remodeling, systolic
dysfunction and sudden cardiac death [49]. In obstructive HCM patients, improvement of
perfusion may be observed when the obstruction is relieved after myectomy (Figure 10) [38,
50].
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Figure 10. Functional imaging of ischemia with single photon‐emission computed tomography (SPECT) with Tc‐99m‐
Sestamibi in a 34‐year‐old male patient with HCM with history of chest pain in the absence of epicardial coronary ar‐
tery disease). Stress (upper row) and rest (lower row). A fixed, non‐reversible defect (scar) in the basal segments of the
LV was found, with a non‐coronary artery distribution. The apical perfusion is normal. However, this pattern may be a
false perfusion defect due to increased hypertrophic mid‐ventricular and apical uptake of the radiotracer. (Reprinted
with permission from Cardim et al. [38]).
Using N‐13‐labelled ammonia and O‐15‐labelled water, proton emission tomography (PET)
imaging detects absolute myocardial blood flow in patients with HCM. In contrast to SPECT,
PET allows the direct quantification of myocardial blood flow (Figure 11) [38]. PET imaging
Figure 11. Functional imaging of ischemia with nuclear proton emission tomography (PET). Stress dipyridamole (up‐
per row) and rest (lower row) 13NH3 perfusion images in an 14‐year‐old girl diagnosed with HCM with interventricu‐
lar septum (IVS) 29 mm. Stress: LV dilation and subendocardial hypoperfusion (IVS and antero‐lateral wall). Rest:
increased IVS 13NH3 uptake is seen, indicative of IVS hypertrophy. (Reprinted with permission from Cardim et al. [38]).
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is the most reliable noninvasive quantitative method for assessing myocardial ischemia in
HCM [51].
3. Summary
Echocardiography remains the first‐line imaging tool in the assessment of HCM patients, while
the role of cardiac MR and nuclear imaging is getting more and more important, providing
specific clinical information, which echocardiography is unable to give. The assessment of
fibrosis, tissue characterization, and myocardial function, represents imaging future priorities
of HCM imaging.
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